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ABSTRACT
Purpose To determine the relationship between retinal
ischaemia and the presence of macular oedema (DMO)
in patients with diabetic retinopathy (DR) using ultra-
wideﬁeld ﬂuorescein angiography (UWFA) imaging.
Methods A retrospective review of 122 eyes of 70
treatment-naı ¨ve diabetic patients who underwent
diagnostic UWFA using the Optos 200Tx imaging
system. Two independent, masked graders quantiﬁed
the area of retinal ischaemia. Based on clinical
examination and optical coherence tomography (OCT),
each patient was given a binary classiﬁcation as either
having DMO or no DMO. McNemar’s test (with Yates’
correction as indicated) and a two-sample test of
proportions were used to determine the relationship
between DMO and ischaemia for binary and proportional
data, respectively. Linear and logistic models were
constructed using generalised estimating equations to
test relationships between independent variables,
covariates and outcomes while controlling for inter-eye
correlation, age, gender, haemoglobin A1c, mean arterial
pressure and dependence on insulin.
Results Seventy-six eyes (62%) exhibited areas of
retinal ischaemia. There was a signiﬁcant direct
correlation between DMO and peripheral retinal
ischaemia as seen on UWFA (p<0.001). In addition,
patients with retinal ischaemia had 3.75 times increased
odds of having DMO compared with those without retinal
ischaemia (CI 1.26 to 11.13, p<0.02).
Conclusion Retinal ischaemia is signiﬁcantly correlated
with DMO in treatment-naı ¨ve patients with DR. UWFA is
a useful tool for detecting peripheral retinal ischaemia,
which may have direct implications in the diagnosis,
follow-up and treatment such as targeted peripheral
photocoagulation.
INTRODUCTION
Diabetic retinopathy (DR) is one of the leading
causes of blindness among adults, accounting for
approximately 5% of global blindness. In parts of
the Americas, Europe and the Western Paciﬁc, DR is
responsible for as much as 17% of the total blind-
ness caused by eye disease.
1 The risk of developing
signiﬁcant visual loss due to DR can be signiﬁcantly
diminished with proper control of systemic disease
and prompt treatment of eye pathology.
1
Diabetic macular oedema (DMO), in particular,
is a major contributor to vision loss among patients
with DR.
2 More than 25 years ago, the Early
Treatment of Diabetic Retinopathy Study (ETDRS)
established guidelines for identifying clinically
signiﬁcant macular oedema (DMO) and proved
that treatment with focal laser photocoagulation
decreased risk of moderate visual loss, increased the
chance of moderate visual gain and reduced retinal
thickening.
3 While ETDRS remains the seminal
study on DMO, additional awareness of diabetic
pathology, the advent of new pharmacology and
improvements in retinal imaging technology have
allowed us to expand upon our understanding and
treatment of DMO.
Ischaemic changes and microvascular pathologies
have long been hypothesised to play a role in the
development of DMO. In DR, ischaemia stimulates
the production of vascular endothelial growth
factor (VEGF),
4 which can lead to the breakdown
of blood-retinal barriers, and may cause DMO
through an increase in retinal vessel permeability.
5
Anti-VEGF drugs have proven efﬁcacious in the
treatment of DMO, even in cases not responding to
laser photocoagulation.
6 The success of anti-VEGF
therapy lends support to the thinking that retinal
ischaemia and DMO are associated, but traditional
retinal imaging of ischaemia makes it difﬁcult to
study this association.
Retinal ischaemia is best characterised with
ﬂuorescein angiography (FA). Traditional FA
employs retinal photography that is able to view
approximately 308 of the retina at one time. The
ETDRS developed the seven-standard ﬁelds (7SF)
protocol in which seven photographed areas of the
retina were combined to give nearly 758 of visual-
isation. With the advent of ultra-wideﬁeld ﬂuores-
cein angiography (UWFA), as with the Optos
200Tx imaging system (Optos PLC, Dunfermline,
Scotland), it is now possible to view up to 2008 of
retina in a single photograph. Initial small-scale
studies have shown that UWFA is more useful in
detecting capillary non-perfusion in patients with
DMO than other methods with a more limited
degree of retinal imaging.
7
The principle aim of this study was to better
characterise the relationship between the area of
retinal ischaemia as measured with UWFA and
the presence of DMO in patients with DR. We
hypothesise that peripheral vascular changes can
inﬂuence the posterior retina and that patients
with retinal ischaemia are at an increased odds of
having DMO. Given the extent of retinal thick-
e n i n gi np a t i e n t sw i t hD M Oc a nb ed e t e r m i n e d
with cross-sectional retinal visualisation in
optical coherence tomography (OCT),
8 this study
also evaluated whether the area of retinal
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Clinical scienceischaemia was correlated with the severity of DMO as eval-
uated by OCT.
METHODS
We present a retrospective review of all patients with DR over
a two-and-a-half-year time period (October 2007 to January
2010) at a single institution who underwent UWFA using the
Optos 200Tx imaging system (Optos PLC, Dunfermine, Scot-
land). The Weill Cornell Medical CollegeeNew York Presbyte-
rian Hospital Institutional Review Board (IRB) approved this
study according to local and national IRB guidelines. Health
Insurance Portability and Accountability Act compliance was
maintained. Care of the patients in this study was in accor-
dance with the Declaration of Helsinki and all federal and state
laws.
All UWFA images were collected according to standard clinic
protocol. Patients received an intravenous injection of 5 cc of
sodium ﬂuorescein 10%. A representative image of each eye was
captured after complete arteriovenous ﬁlling, using the Optos
V2 Vantage Review Software. Images were compressed into
high quality jpeg ﬁles, transferred to Adobe software and
evaluated by two independent trained masked graders for the
presence of retinal ischaemia. For the purpose of this study,
retinal ischaemia was deﬁned as angiographically visually
signiﬁcant hypoﬂuorescence of an area of at least one disc
diameter (representing retinal non-perfusion or capillary
dropout) or areas of microvascular pathology (multiple micro-
aneurysms, intraretinal microvascular anomalies and signiﬁcant
perivascular leakage) with associated capillary pruning of at
least one disc diameter. Given that delineation of ischaemic
retina on FA can be challenging, graders were thoroughly
trained prior to analysing images for the study in using various
controls in Adobe software (ie, brightness, contrast, level,
zoom) and how to ignore eyelashes and peripheral blurring that
be mistaken for non-perfusion. Preliminary sample images were
reviewed together and remaining areas of disagreement were
reviewed with the senior author. Once good correlation was
documented with sample images, the graders independently
analysed the 236 UWFA images included in the study. A total
retinal surface area, as well as the area of retinal ischaemia was
measured in pixels (ﬁgure 1A,B). The data was then averaged
between the two graders to obtain ﬁnal values. Lin correlation
coefﬁcients were calculated and >0.80 was considered sufﬁcient
to prove a strong inter-grader correlation. Had any data fallen
below this value, a third grader would have been used to resolve
discrepancies; however, this step was unnecessary. The
proportion of ischaemic to total visible retinal area was calcu-
lated for each image.
For each diabetic patient who received UWFA during the
period of interest, it was noted whether a clinical diagnosis of
DMO was made in the chart during dilated fundoscopy. The
following information was also obtained from the electronic
medical record: age, gender, haemoglobin A1c, mean arterial
pressure (MAP) and dependence on insulin. MAP and haemo-
globin A1c values were used only if they were within 3 months
of the UWFA image collection. If a patient presented for UWFA
on multiple occasions, the earliest clinical visit was evaluated.
Exclusion criteria consisted of the following: eyes that had
undergone retinal surgery or laser treatment, eyes that had
received intravitreal injections, eyes with concomitant non-dia-
betic pathology (including artery and vein occlusions, uveitis,
sickle cell retinopathy) as identiﬁed by either angiography or
clinical history, eyes with >5 disc diameters of chorioretinal
scarring, eyes with tumours, eyes that were poorly photo-
graphed due to signiﬁcant media opacities (vitreous haemor-
rhage, cataract) or poor patient cooperation (eyelids covering at
least one quarter of retinal image).
Additionally, where available, OCT (Heidelberg Spectralis
HRA+OCT, Heidelberg Engineering, Germany) images were
analysed to detect the presence and extent of DMO. OCT
images were only considered relevant if they were collected on
the same day as the UWFA images. Values for central macular
thickness (1 mm diameter, centred on the fovea), and the central
macular volume (both 1 mm and 3 mm diameters, centred on
the fovea) were obtained using Heidelberg Eye Explorer software
in accordance with ETDRS protocol.
All analyses were conducted using Stata 11/IC software
(StataCorp LP, College Station, Texas, USA). McNemar’s test
and a two-sample test of proportions were used to determine
the relationship between DMO and ischaemia for binary and
proportional data, respectively. Associations of binary, contin-
uous and proportional dependent variables with covariates and
predictors of interest were modelled using generalised estimating
equations to control for inter-eye correlation among patients. All
statistical tests were two-sided with a 0.05 level of signiﬁcance.
Figure 1 (A): A sample ultra-wideﬁeld ﬂuorescein angiogram. Retinal
ischaemia is outlined in red. To obtain the proportion of ischaemic to
total retina, the pixels enclosed by the outlined area were divided into
the total pixels of the image. (B): A close-up view of the superonasal
quadrant of (A) showing the difference between ischaemic (I) and non-
ischaemic (N) retina. Retinal ischaemia is deﬁned as angiographically
visually signiﬁcant hypoﬂuorescence (capillary dropout) or areas of
signiﬁcant capillary pruning associated with microvascular pathology
(microaneurysms, intraretinal microvascular anomalies, perivascular
leakage). Note that the ground glass appearance and normal capillary
architecture of the non-ischaemic retina differs from the hypoﬂuorescent
areas of non-perfusion and ischaemic vasculature highlighted in red. This
ﬁgure is produced in colour in the online journaldplease visit the
website to view the colour ﬁgure.
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A total of 236 UWFAs from 118 diabetic patients were reviewed.
One hundred and fourteen eyes were excluded from the study
(table 1) leaving a total of 122 treatment-naïve eyes of 70 dia-
betic patients. Patients ranged in age from 18 to 87 years
(median 60 years). Eyes being evaluated were initially separated
into two categories based on electronic medical record chart
diagnoses: DMO (24 eyes) or no DMO (98 eyes). The median
age of patients with at least one eye with DMO was 58 years,
and 50% of these patients were male. The median age of patients
with no DMO in either eye was 60 years, and 41% were male.
Each eye was also evaluated for presence or absence of retinal
ischaemia using UWFA images. Out of 122 eyes, 76 demon-
strated some degree of ischaemia. The binary classiﬁcation of
DMO was compared with the binary classiﬁcation of ischaemia
(table 2) and the two were found to be signiﬁcantly related
(p<0.001). Furthermore, the odds of having DMO in patients
with retinal ischaemia were calculated (table 3). This analysis
adjusted for several covariates, including MAP and haemoglobin
A1c (if available within 3 months of UWFA) as well as age. Eyes
with retinal ischaemia had signiﬁcantly higher odds of having
DMO (OR¼3.75, 95% CI 1.26 to 11.13, p¼0.02). There was no
signiﬁcant association between odds of DMO and haemoglobin
A1c (OR¼1.34, 95% CI 0.61 to 2.93, p¼0.47), MAP (OR¼1.00,
95% CI 0.94 to 1.06, p¼0.99), or age (OR¼1.01, 95% CI 0.96 to
1.07, p¼0.68) on univariable analysis. However, among patients
with demonstrable ischaemia on UWFA, haemoglobin A1c level
was signiﬁcantly associated with the proportion of retina found
to be ischaemic (ß¼0.34, 95% CI 0.07 to 0.61, p¼0.01) (ﬁgure 2).
Although binary classiﬁcation of ischaemia was signiﬁcantly
associated with presence or absence of DMO, we did not ﬁnd
a signiﬁcant relationship between DMO and the proportion of
ischaemic retina (p¼0.88). Furthermore, among the 18 eyes for
which there were both UWFA and OCT images, there was no
signiﬁcant relationship between proportion of ischaemic retina
and extent of DMO based on OCT image analysis (r¼0.05,
p¼0.86).
DISCUSSION
Since ﬁrst described by Friberg and Forrester in 2004,
9 UWFA has
proven to be a reliable method of retinal evaluation, having
favourable sensitivity and speciﬁcity compared with other
traditional methods.
10e12 In some applications, including iden-
tiﬁcation of diabetic pathology, it has proven to be superior to
traditional methods, including 7SF. A recent comprehensive
study of efﬁcacy in detection of diabetic pathology found that
UWFA was able to demonstrate retinal non-perfusion and
neovascularisation in 10% of eyes that would have been missed
by 7SF.
13
To our knowledge, this study is one of the ﬁrst and largest to
use UWFA to evaluate retinal ischaemia and identify its rela-
tionship with DMO. This study also examined whether UWFA
can be used as a complement to OCT to determine whether the
degree of macular thickening correlates with the proportion of
retinal ischaemia.
We demonstrate that patients with retinal ischaemia have
a 3.75 times greater chance of having DMO. This observation
has several important implications. First, it lends support to the
growing data suggesting that retinal ischaemia and release of
vasoproliferative growth factors play a role in the pathogenesis
of DMO. Several recent studies, including the BOLT and
PACORES study groups, have shown that anti-VEGF therapy is
effective in treating DMO, even in cases where macular laser
therapy has failed.
14e16 In that retinal ischaemia is most likely
driving the release of VEGF, and that patients with retinal
ischaemia have a 3.75 times greater chance of developing DMO,
detection and monitoring of peripheral retinal ischaemia could
play an important role in the management of patients with
diabetic retinopathy. For example, patients with retinal
ischaemia on UWFA may necessitate closer monitoring and
earlier follow-up than patients with no evidence of retinal
ischaemia.
A second implication of our study is that new treatment
modalities, such as targeted retinal photocoagulation (TRP) may
prove efﬁcacious in treating DMO. In early studies evaluating
patients with proliferative diabetic retinopathy, it has been
suggested that TRP may replace pan-retinal photocoagulation
by directing therapy speciﬁcally at ischaemic parts of the retina
to precisely eliminate the source of VEGF, thus minimising the
sequelae of pan-retinal photocoagulation.
17 In many of the eyes
that we analysed, DMO was present despite minimal posterior
diabetic pathology. In some of these eyes, UWFA was able to
demonstrate anterior areas of retinal ischaemia (ﬁgure 3). In that
Table 1 Exclusion criteria and number of excluded eyes
Exclusion criteria No. of eyes excluded
Previous retinal treatment




Artery and vein occlusion 4
Uveitis 2
Sickle cell 1





Limited view (eyelids covering >1/4 of simulated 7SF) 1
Total 114
PRP, Pan-retinal photocoagulation; 7SF, seven-standard ﬁelds.





No 42 4 46
Yes 56 20 76
Total 98 24 122
McNemar’s test: c
2¼45.07, p<0.001 (with Yate’s correction).
Table 3 There are signiﬁcantly increased odds of macular oedema in
patients with evidence of retinal ischaemia
OR (95% CI) p Value
Univariate (n¼122)
Ischaemia 3.75 (1.26 to 11.13) 0.02
Multivariate*(n¼78)
Ischaemia 6.63 (1.49 to 29.58) 0.01
A1c 1.34 (0.61 to 2.93) 0.47
MAP 1.00 (0.94 to 1.06) 0.99
Age 1.01 (0.96 to 1.07) 0.68
*Only included A1c, MAP (mean arterial pressure) data if within 3 months of ﬂuorescein
angiography.
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related to peripheral retinal ischaemia in these cases, it would be
reasonable to consider treating DMO by using UWFA and TRP.
In combination with macular laser and anti-VEGF therapy, TRP
could prove to be important in the growing arsenal of treatment
modalities for DMO.
Interestingly, our study failed to detect an association
between the amount of retinal ischaemia and the degree of
macular thickening. While this might in part be attributable to
the small number of patients who had both OCT and UWFA
images performed at the time of their initial visit, it might also
suggest that the degree of retinal ischaemia is not related to the
extent of macular thickening. It is possible that only a small
amount of retinal ischaemia is necessary for the causal factors of
DMO to develop, and the macular thickness may be more
attributable to local, structural and micro-anatomical factors
than to the extent of released VEGF. Additional studies would be
needed to explore this relationship further. Also, it was also
noted that the proportion of retinal ischaemia was signiﬁcantly
related to the value of haemoglobin A1c (ﬁgure 2), but not with
the presence of DMO. This could suggest that both DMO and
ischaemia are related to the pathophysiology of diabetes, but by
different mechanisms. Along with evaluating whether there is
a direct association between ischaemia and DMO, it would be
valuable to examine whether there is a threshold level of
ischaemia at which DMO is induced.
We recognise there are limitations to the conclusions that can
be drawn from our study. Although we attempted to use all
UWFAs in the two-and-a-half-year time period, there was likely
a signiﬁcant selection bias given that physicians had multiple
options of obtaining ﬂuorescein angiograms in our clinic, only
one of which was the Optos system. Given the retrospective
nature of our study and the limited time span in which the
study was conducted, we realise that not all results are gener-
alisable. However, the large number of patients included in the
study helps to mitigate this issue. While this is, to our knowl-
edge, the largest study examining the correlation between retinal
ischaemia and DMO, further studies with an increased number
of patients would enhance our ﬁndings, and prospective trials
could help validate these potential applications of UWFA in
clinical practice. Additionally, we realise that measurements of
a three-dimensional eye using a two-dimensional system are
imprecise, and it is likely that peripheral pathology is over-
represented. While not trivial, this discrepancy would not
signiﬁcantly alter the conclusions that can be drawn from our
data. Finally, while identifying the presence of retinal ischaemia
on UWFA imaging is fairly straightforward, variations in image
quality could lead to some variability in quantifying the area of
ischaemic retina in each image. These limitations were mini-
mised by our large sample size and the use of two independent
reviewers to evaluate each image.
Overall, the ﬁndings of this study suggest that there may be
a role for UWFA in assessing retinal changes associated with
DMO. UWFA may serve as a valuable tool for identifying dia-
betic patients at risk of developing DMO, for guiding manage-
ment and follow-up protocols, and for potential new treatment
options. As DMO contributes signiﬁcantly to vision loss in
patients with diabetes, the possibility of using UWFA to develop
earlier and more precise detection and treatment strategies for
DMO is encouraging.
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